世界の肝胆道疾患向けウルソデオキシコール酸製剤市場予測2023-2029:カプセル、錠剤

【英語タイトル】Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが出版した調査資料(MMG23FB2519)・商品コード:MMG23FB2519
・発行会社(調査会社):Market Monitor Global
・発行日:2023年2月
・ページ数:72
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後2-3営業日)
・調査対象地域:グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,250 ⇒換算¥494,000見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD4,225 ⇒換算¥642,200見積依頼/購入/質問フォーム
Enterprise User(閲覧人数制限なし)USD4,875 ⇒換算¥741,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界の肝胆道疾患向けウルソデオキシコール酸製剤市場規模と予測を収録しています。・世界の肝胆道疾患向けウルソデオキシコール酸製剤市場:売上、2018年-2023年、2024年-2029年
・世界の肝胆道疾患向けウルソデオキシコール酸製剤市場:販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の肝胆道疾患向けウルソデオキシコール酸製剤市場は2022年に000Mドルと評価され、予測期間中に000%のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「カプセル」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

肝胆道疾患向けウルソデオキシコール酸製剤のグローバル主要企業は、Dr. Falk Pharma、Daewoong Pharmaceutical、Teva、Humanwell、Mitsubishi Tanabe Pharma、Lannett、Mylan、Bruschettini、Impax、Shanghai Pharma、Grindeksなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL(MMG)は、肝胆道疾患向けウルソデオキシコール酸製剤のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の肝胆道疾患向けウルソデオキシコール酸製剤市場:タイプ別、2018年-2023年、2024年-2029年
世界の肝胆道疾患向けウルソデオキシコール酸製剤市場:タイプ別市場シェア、2022年
・カプセル、錠剤

世界の肝胆道疾患向けウルソデオキシコール酸製剤市場:用途別、2018年-2023年、2024年-2029年
世界の肝胆道疾患向けウルソデオキシコール酸製剤市場:用途別市場シェア、2022年
・原発性胆汁性肝硬変(PBC)、胆石、その他

世界の肝胆道疾患向けウルソデオキシコール酸製剤市場:地域・国別、2018年-2023年、2024年-2029年
世界の肝胆道疾患向けウルソデオキシコール酸製剤市場:地域別市場シェア、2022年
・北米:アメリカ、カナダ、メキシコ
・ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
・アジア:中国、日本、韓国、東南アジア、インド
・南米:ブラジル、アルゼンチン
・中東・アフリカ:トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における肝胆道疾患向けウルソデオキシコール酸製剤のグローバル売上、2018年-2023年
・主要企業における肝胆道疾患向けウルソデオキシコール酸製剤のグローバル売上シェア、2022年
・主要企業における肝胆道疾患向けウルソデオキシコール酸製剤のグローバル販売量、2018年-2023年
・主要企業における肝胆道疾患向けウルソデオキシコール酸製剤のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Dr. Falk Pharma、Daewoong Pharmaceutical、Teva、Humanwell、Mitsubishi Tanabe Pharma、Lannett、Mylan、Bruschettini、Impax、Shanghai Pharma、Grindeks

*************************************************************

・調査・分析レポートの概要
肝胆道疾患向けウルソデオキシコール酸製剤市場の定義
市場セグメント
世界の肝胆道疾患向けウルソデオキシコール酸製剤市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の肝胆道疾患向けウルソデオキシコール酸製剤市場規模
世界の肝胆道疾患向けウルソデオキシコール酸製剤市場規模:2022年 VS 2029年
世界の肝胆道疾患向けウルソデオキシコール酸製剤市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの肝胆道疾患向けウルソデオキシコール酸製剤の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の肝胆道疾患向けウルソデオキシコール酸製剤製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分:カプセル、錠剤
肝胆道疾患向けウルソデオキシコール酸製剤のタイプ別グローバル売上・予測

・用途別市場分析
用途区分:原発性胆汁性肝硬変(PBC)、胆石、その他
肝胆道疾患向けウルソデオキシコール酸製剤の用途別グローバル売上・予測

・地域別市場分析
地域別肝胆道疾患向けウルソデオキシコール酸製剤市場規模 2022年と2029年
地域別肝胆道疾患向けウルソデオキシコール酸製剤売上・予測
北米市場:アメリカ、カナダ、メキシコ
ヨーロッパ市場:ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場:中国、日本、韓国、東南アジア、インド
南米市場:ブラジル、アルゼンチン
中東・アフリカ市場:トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル(企業概要、事業概要、主要製品、売上、ニュースなど)
Dr. Falk Pharma、Daewoong Pharmaceutical、Teva、Humanwell、Mitsubishi Tanabe Pharma、Lannett、Mylan、Bruschettini、Impax、Shanghai Pharma、Grindeks

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Overall Market Size
2.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size: 2022 VS 2029
2.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales: 2018-2029
3 Company Landscape
3.1 Top Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Players in Global Market
3.2 Top Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Companies Ranked by Revenue
3.3 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue by Companies
3.4 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Companies
3.5 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Type
3.8 Tier 1, Tier 2 and Tier 3 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Players in Global Market
3.8.1 List of Global Tier 1 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Companies
3.8.2 List of Global Tier 2 and Tier 3 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size Markets, 2022 & 2029
4.1.2 Capsule
4.1.3 Tablet
4.2 By Type – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue & Forecasts
4.2.1 By Type – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, 2018-2023
4.2.2 By Type – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, 2024-2029
4.2.3 By Type – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue Market Share, 2018-2029
4.3 By Type – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales & Forecasts
4.3.1 By Type – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, 2018-2023
4.3.2 By Type – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, 2024-2029
4.3.3 By Type – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Market Share, 2018-2029
4.4 By Type – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2022 & 2029
5.1.2 Primary Biliary Cirrhosis(PBC)
5.1.3 Gallstones
5.1.4 Others
5.2 By Application – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue & Forecasts
5.2.1 By Application – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, 2018-2023
5.2.2 By Application – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, 2024-2029
5.2.3 By Application – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue Market Share, 2018-2029
5.3 By Application – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales & Forecasts
5.3.1 By Application – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, 2018-2023
5.3.2 By Application – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, 2024-2029
5.3.3 By Application – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Market Share, 2018-2029
5.4 By Application – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2022 & 2029
6.2 By Region – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue & Forecasts
6.2.1 By Region – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, 2018-2023
6.2.2 By Region – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, 2024-2029
6.2.3 By Region – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue Market Share, 2018-2029
6.3 By Region – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales & Forecasts
6.3.1 By Region – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, 2018-2023
6.3.2 By Region – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, 2024-2029
6.3.3 By Region – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, 2018-2029
6.4.2 By Country – North America Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, 2018-2029
6.4.3 US Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.4.4 Canada Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.4.5 Mexico Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, 2018-2029
6.5.2 By Country – Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, 2018-2029
6.5.3 Germany Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.5.4 France Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.5.5 U.K. Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.5.6 Italy Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.5.7 Russia Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.5.8 Nordic Countries Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.5.9 Benelux Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, 2018-2029
6.6.2 By Region – Asia Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, 2018-2029
6.6.3 China Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.6.4 Japan Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.6.5 South Korea Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.6.6 Southeast Asia Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.6.7 India Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, 2018-2029
6.7.2 By Country – South America Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, 2018-2029
6.7.3 Brazil Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.7.4 Argentina Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, 2018-2029
6.8.3 Turkey Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.8.4 Israel Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.8.5 Saudi Arabia Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.8.6 UAE Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Dr. Falk Pharma
7.1.1 Dr. Falk Pharma Company Summary
7.1.2 Dr. Falk Pharma Business Overview
7.1.3 Dr. Falk Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Major Product Offerings
7.1.4 Dr. Falk Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales and Revenue in Global (2018-2023)
7.1.5 Dr. Falk Pharma Key News & Latest Developments
7.2 Daewoong Pharmaceutical
7.2.1 Daewoong Pharmaceutical Company Summary
7.2.2 Daewoong Pharmaceutical Business Overview
7.2.3 Daewoong Pharmaceutical Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Major Product Offerings
7.2.4 Daewoong Pharmaceutical Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales and Revenue in Global (2018-2023)
7.2.5 Daewoong Pharmaceutical Key News & Latest Developments
7.3 Teva
7.3.1 Teva Company Summary
7.3.2 Teva Business Overview
7.3.3 Teva Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Major Product Offerings
7.3.4 Teva Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales and Revenue in Global (2018-2023)
7.3.5 Teva Key News & Latest Developments
7.4 Humanwell
7.4.1 Humanwell Company Summary
7.4.2 Humanwell Business Overview
7.4.3 Humanwell Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Major Product Offerings
7.4.4 Humanwell Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales and Revenue in Global (2018-2023)
7.4.5 Humanwell Key News & Latest Developments
7.5 Mitsubishi Tanabe Pharma
7.5.1 Mitsubishi Tanabe Pharma Company Summary
7.5.2 Mitsubishi Tanabe Pharma Business Overview
7.5.3 Mitsubishi Tanabe Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Major Product Offerings
7.5.4 Mitsubishi Tanabe Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales and Revenue in Global (2018-2023)
7.5.5 Mitsubishi Tanabe Pharma Key News & Latest Developments
7.6 Lannett
7.6.1 Lannett Company Summary
7.6.2 Lannett Business Overview
7.6.3 Lannett Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Major Product Offerings
7.6.4 Lannett Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales and Revenue in Global (2018-2023)
7.6.5 Lannett Key News & Latest Developments
7.7 Mylan
7.7.1 Mylan Company Summary
7.7.2 Mylan Business Overview
7.7.3 Mylan Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Major Product Offerings
7.7.4 Mylan Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales and Revenue in Global (2018-2023)
7.7.5 Mylan Key News & Latest Developments
7.8 Bruschettini
7.8.1 Bruschettini Company Summary
7.8.2 Bruschettini Business Overview
7.8.3 Bruschettini Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Major Product Offerings
7.8.4 Bruschettini Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales and Revenue in Global (2018-2023)
7.8.5 Bruschettini Key News & Latest Developments
7.9 Impax
7.9.1 Impax Company Summary
7.9.2 Impax Business Overview
7.9.3 Impax Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Major Product Offerings
7.9.4 Impax Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales and Revenue in Global (2018-2023)
7.9.5 Impax Key News & Latest Developments
7.10 Shanghai Pharma
7.10.1 Shanghai Pharma Company Summary
7.10.2 Shanghai Pharma Business Overview
7.10.3 Shanghai Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Major Product Offerings
7.10.4 Shanghai Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales and Revenue in Global (2018-2023)
7.10.5 Shanghai Pharma Key News & Latest Developments
7.11 Grindeks
7.11.1 Grindeks Company Summary
7.11.2 Grindeks Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Business Overview
7.11.3 Grindeks Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Major Product Offerings
7.11.4 Grindeks Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales and Revenue in Global (2018-2023)
7.11.5 Grindeks Key News & Latest Developments
8 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Production Capacity, Analysis
8.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Production Capacity, 2018-2029
8.2 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Production Capacity of Key Manufacturers in Global Market
8.3 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Supply Chain Analysis
10.1 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Industry Value Chain
10.2 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Upstream Market
10.3 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases in Global Market
Table 2. Top Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue Share by Companies, 2018-2023
Table 5. Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Companies, (K Units), 2018-2023
Table 6. Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Type
Table 9. List of Global Tier 1 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales (K Units), 2018-2023
Table 15. By Type - Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales (K Units), 2024-2029
Table 16. By Application – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales (K Units), 2018-2023
Table 20. By Application - Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales (K Units), 2024-2029
Table 21. By Region – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales (K Units), 2018-2023
Table 25. By Region - Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales (K Units), 2024-2029
Table 26. By Country - North America Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, (K Units), 2018-2023
Table 29. By Country - North America Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, (K Units), 2024-2029
Table 30. By Country - Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, (K Units), 2018-2023
Table 33. By Country - Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, (K Units), 2024-2029
Table 34. By Region - Asia Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, (K Units), 2018-2023
Table 37. By Region - Asia Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, (K Units), 2024-2029
Table 38. By Country - South America Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, (K Units), 2018-2023
Table 41. By Country - South America Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, (K Units), 2024-2029
Table 46. Dr. Falk Pharma Company Summary
Table 47. Dr. Falk Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Offerings
Table 48. Dr. Falk Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. Dr. Falk Pharma Key News & Latest Developments
Table 50. Daewoong Pharmaceutical Company Summary
Table 51. Daewoong Pharmaceutical Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Offerings
Table 52. Daewoong Pharmaceutical Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. Daewoong Pharmaceutical Key News & Latest Developments
Table 54. Teva Company Summary
Table 55. Teva Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Offerings
Table 56. Teva Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. Teva Key News & Latest Developments
Table 58. Humanwell Company Summary
Table 59. Humanwell Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Offerings
Table 60. Humanwell Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. Humanwell Key News & Latest Developments
Table 62. Mitsubishi Tanabe Pharma Company Summary
Table 63. Mitsubishi Tanabe Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Offerings
Table 64. Mitsubishi Tanabe Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 65. Mitsubishi Tanabe Pharma Key News & Latest Developments
Table 66. Lannett Company Summary
Table 67. Lannett Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Offerings
Table 68. Lannett Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 69. Lannett Key News & Latest Developments
Table 70. Mylan Company Summary
Table 71. Mylan Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Offerings
Table 72. Mylan Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 73. Mylan Key News & Latest Developments
Table 74. Bruschettini Company Summary
Table 75. Bruschettini Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Offerings
Table 76. Bruschettini Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 77. Bruschettini Key News & Latest Developments
Table 78. Impax Company Summary
Table 79. Impax Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Offerings
Table 80. Impax Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 81. Impax Key News & Latest Developments
Table 82. Shanghai Pharma Company Summary
Table 83. Shanghai Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Offerings
Table 84. Shanghai Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 85. Shanghai Pharma Key News & Latest Developments
Table 86. Grindeks Company Summary
Table 87. Grindeks Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Offerings
Table 88. Grindeks Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 89. Grindeks Key News & Latest Developments
Table 90. Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 91. Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Capacity Market Share of Key Manufacturers, 2021-2023
Table 92. Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Production by Region, 2018-2023 (K Units)
Table 93. Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Production by Region, 2024-2029 (K Units)
Table 94. Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Opportunities & Trends in Global Market
Table 95. Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Drivers in Global Market
Table 96. Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Restraints in Global Market
Table 97. Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Raw Materials
Table 98. Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Raw Materials Suppliers in Global Market
Table 99. Typical Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Downstream
Table 100. Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Downstream Clients in Global Market
Table 101. Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Segment by Type in 2022
Figure 2. Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Segment by Application in 2022
Figure 3. Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, 2018-2029 (US$, Mn)
Figure 7. Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue in 2022
Figure 9. By Type - Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue Market Share, 2018-2029
Figure 11. By Type - Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Market Share, 2018-2029
Figure 12. By Type - Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Price (US$/Unit), 2018-2029
Figure 13. By Application - Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue Market Share, 2018-2029
Figure 15. By Application - Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Market Share, 2018-2029
Figure 16. By Application - Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Price (US$/Unit), 2018-2029
Figure 17. By Region - Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue Market Share, 2018-2029
Figure 20. By Region - Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Market Share, 2018-2029
Figure 21. By Country - North America Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue Market Share, 2018-2029
Figure 22. By Country - North America Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Market Share, 2018-2029
Figure 23. US Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Market Share, 2018-2029
Figure 28. Germany Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2018-2029
Figure 29. France Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Market Share, 2018-2029
Figure 37. China Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2018-2029
Figure 41. India Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue Market Share, 2018-2029
Figure 43. By Country - South America Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Market Share, 2018-2029
Figure 44. Brazil Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Market Share, 2018-2029
Figure 48. Turkey Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, (US$, Mn), 2018-2029
Figure 52. Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Region, 2022 VS 2029
Figure 54. Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Industry Value Chain
Figure 55. Marketing Channels


★調査レポート[世界の肝胆道疾患向けウルソデオキシコール酸製剤市場予測2023-2029:カプセル、錠剤] (コード:MMG23FB2519)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の肝胆道疾患向けウルソデオキシコール酸製剤市場予測2023-2029:カプセル、錠剤]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆